From Avastin To Zevalin: ODAC’s Most Memorable Moments
The current and former leaders of FDA’s Oncologic Drugs Advisory Committee recount their most memorable moments of service on the panel.
You may also be interested in...
Current and former chairs of FDA’s Oncologic Drugs Advisory Committee debate the usefulness of the public hearing and its impact on committee deliberations.
Rather than damaging the use of progression-free survival as an endpoint in oncology clinical trials, as some have feared, the battle over Avastin’s (bevacizumab) metastatic breast cancer claim could give sponsors some clarity as to how FDA expects the magnitude of PFS benefit to be defined.
Tempers frayed as the FDA Oncologic Drugs Advisory Committee gathered to review GlaxoSmithKline's Avodart (dutasteride) and Merck's Proscar (finasteride) for prostate cancer prevention Dec. 1.